Dosage of erythropoietin stimulating agent has been reduced and maintained in response to hematocrit or hemoglobin level.

This modifier is used for national claims monitoring for ESAs administered in Medicare renal dialysis facilities, so therefore, is not applicable to Part B.

Reference: CMS Medicare Claims Processing Manual (Pub. 100-04), Chapter 8, Section 60.4 (PDF, 1.82 MB).

Contact Palmetto GBA JJ Part B Medicare

Provider Contact Center: 877-567-7271

Email JJ Part B

Contact a specific JJ Part B department

Click to Chat Now